A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Eli Lilly and Company
Study ID
NCT07215312
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3938577 — DRUG
    Administered SC
  • Degludec — DRUG
    Administered SC

Study Details

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Key Dates

Start date
Oct 13, 2025
Status verified
May 2026
Primary completion
Nov 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: LY3938577
    Participants will receive LY3938577 subcutaneously (SC)
  • Active Comparator: Degludec
    Participants will receive degludec SC

Primary Outcome Measure

Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis) [ Time Frame: Baseline through Week 20 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (20)

FacilityCityStateZIPSite coordinators
Tucson Clinical Research InstituteTucsonArizona85712-
Encompass Clinical ResearchSpring ValleyCalifornia91978-
University Clinical Investigators, Inc.TustinCalifornia92780
714-734-7944
Joanna Van (PRINCIPAL_INVESTIGATOR)
Tampa Bay Medical ResearchClearwaterFlorida33761
727-724-3316
Sureka Bollepalli (PRINCIPAL_INVESTIGATOR)
Encore Medical ResearchHollywoodFlorida33024-
Clinical Research of Central FloridaLakelandFlorida33805-
Encore Medical Research - WestonWestonFlorida33331
954-777-8827
Sandro Bacchelli (PRINCIPAL_INVESTIGATOR)
Iowa Diabetes and Endocrinology Research CenterWest Des MoinesIowa50266-
Washington University School of MedicineSt LouisMissouri63110-
Accellacare - WilmingtonWilmingtonNorth Carolina28401
910-799-5500
John Parker (PRINCIPAL_INVESTIGATOR)
AMR ClinicalNormanOklahoma73069-
Tribe Clinical Research, LLCGreenvilleSouth Carolina29607-
Holston Medical GroupBristolTennessee37620
423-990-2478
Rick Whiles (PRINCIPAL_INVESTIGATOR)
Texas Diabetes & Endocrinology, P.A.AustinTexas78749-
Velocity Clinical Research, DallasDallasTexas75230-
Juno ResearchHoustonTexas77040
713-779-5494
Damaris Vega (PRINCIPAL_INVESTIGATOR)
Southern Endocrinology AssociatesMesquiteTexas75149-
Consano Clinical Research, LLCShavano ParkTexas78231-
Texas Valley Clinical ResearchWeslacoTexas78596
956-431-8090
Eduardo Luna (PRINCIPAL_INVESTIGATOR)
Chrysalis Clinical ResearchSt. GeorgeUtah84790
435-656-1704
Joseph Woolley (PRINCIPAL_INVESTIGATOR)

Find similar trials in Tucson, AZ

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Tucson Clinical Research Institute· Tucson, AZEncompass Clinical Research· Spring Valley, CAUniversity Clinical Investigators, Inc.· Tustin, CATampa Bay Medical Research· Clearwater, FLEncore Medical Research· Hollywood, FLClinical Research of Central Florida· Lakeland, FL

Related Studies